{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:40:05Z","timestamp":1746340805435,"version":"3.40.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Science and Technology Commission","award":["C201929381"],"award-info":[{"award-number":["C201929381"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Reversing left ventricular hypertrophy (LVH) can reduce the incidence of adverse cardiovascular events. The lack of direct comparison between different antihypertensive drugs cannot evaluate the superiority-inferiority differentiation of different antihypertensive drugs in reversing LVH. Therefore, the objective of this protocol for systematic review and meta-analysis was to compare the efficacy of different types of antihypertensive drugs in reversing LVH in hypertensive patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement guidelines. Studies were identified through systematic searches in June 2021 with no restrictions on date and time, language, and publication status using the following bibliographic databases: Embase, Medline, PubMed, Web of Science, Science Direct, and the Cochrane Library. The risk of bias assessment of the included studies was performed by two authors independently using the tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). All calculations were carried out with Stata 11.0 (The Cochrane Collaboration, Oxford, United Kingdom).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>We hypothesized that the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in antihypertensive therapy could achieve better efficacy in reversing LVH in hypertensive patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026455","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:16:35Z","timestamp":1624454195000},"page":"e26455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients"],"prefix":"10.1097","volume":"100","author":[{"given":"Hao","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Ultrasound"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The People's Hospital of Fenghua"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-8549","authenticated-orcid":false,"given":"Yong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Ningbo No. 1 Hospital, Ningbo, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can J Cardiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e12457","DOI":"10.1161\/JAHA.119.012457","article-title":"Is electrocardiography-left ventricular hypertrophy an obsolete marker for determining heart failure risk with hypertension?","volume":"8","author":"Ferdinand","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jch.13919","article-title":"Modified Cornell electrocardiographic criteria in the assessment of left ventricular hypertrophy geometry of patients with essential hypertension","volume":"22","author":"Xu","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jch.13793","article-title":"Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes","volume":"22","author":"Zhang","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12968-020-00655-7","article-title":"Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy","volume":"22","author":"Kwiecinski","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"(3.)","key":"R6-20250504","article-title":"Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network)","volume":"6","author":"Lonnebakken","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R7-20250504","first-page":"571","article-title":"2017\u200aACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"12","author":"Whelton","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MD.0000000000000130","article-title":"Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis","volume":"93","author":"Zhang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.15190\/d.2020.12","article-title":"Regression of the left ventricular hypertrophy in patients with essential hypertension on standard drug therapy","volume":"8","author":"Ahmed","year":"2020","journal-title":"Discoveries (Craiova)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1253\/circj.CJ-16-0062","article-title":"From left ventricular hypertrophy to dysfunction and failure","volume":"80","author":"Lazzeroni","year":"2016","journal-title":"Circ J"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e11961","DOI":"10.1161\/JAHA.119.011961","article-title":"Prevention of heart failure in hypertension-disentangling the role of evolving left ventricular hypertrophy and blood pressure lowering: The ALLHAT Study","volume":"8","author":"Johnson","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00228-005-0931-8","article-title":"Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension","volume":"61","author":"Anan","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/HJH.0000000000000280","article-title":"Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension","volume":"32","author":"Azizi","year":"2014","journal-title":"J Hypertens"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:08Z","timestamp":1746338708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026455"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":14,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026455","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2021-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}